Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 710

1.

Surgical consent practice in the UK following the Montgomery ruling: A national cross-sectional questionnaire study.

McKinnon C, Loughran D, Finn R, Coxwell-Matthewman M, Jeyaretna DS, Williams AP.

Int J Surg. 2018 May 15. pii: S1743-9191(18)30763-5. doi: 10.1016/j.ijsu.2018.05.016. [Epub ahead of print]

PMID:
29775736
2.

Benchmarking taxonomic assignments based on 16S rRNA gene profiling of the microbiota from commonly sampled environments.

Almeida A, Mitchell AL, Tarkowska A, Finn RD.

Gigascience. 2018 May 11. doi: 10.1093/gigascience/giy054. [Epub ahead of print]

PMID:
29762668
3.

Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase 3 RESORCE trial.

Finn RS, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Gerolami R, Caparello C, Cabrera R, Chang C, Sun W, LeBerre MA, Baumhauer A, Meinhardt G, Bruix J; RESORCE Investigators.

J Hepatol. 2018 Apr 25. pii: S0168-8278(18)32018-X. doi: 10.1016/j.jhep.2018.04.010. [Epub ahead of print]

PMID:
29704513
4.

The Use of Allogeneic Cartilage for Grafting in Functional and Reconstructive Rhinoplasty.

Read-Fuller AM, Yates DM, Radwan A, Schrodt AM, Finn RA.

J Oral Maxillofac Surg. 2018 Mar 27. pii: S0278-2391(18)30279-9. doi: 10.1016/j.joms.2018.03.021. [Epub ahead of print]

PMID:
29673851
5.

A Novel Multimarker Assay for the Phenotypic Profiling of Circulating Tumor Cells in Hepatocellular Carcinoma.

Court CM, Hou S, Winograd P, Segel NH, Li QW, Zhu Y, Sadeghi S, Finn RS, Ganapathy E, Song M, French SW, Naini BV, Sho S, Kaldas FM, Busuttil RW, Tomlinson JS, Tseng HR, Agopian VG.

Liver Transpl. 2018 Apr 6. doi: 10.1002/lt.25062. [Epub ahead of print]

PMID:
29624843
6.

Diagnosis, Staging and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.

Marrero JA, Kulik LM, Sirlin C, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK.

Hepatology. 2018 Apr 6. doi: 10.1002/hep.29913. [Epub ahead of print] No abstract available.

PMID:
29624699
7.

Multiple Cranial Neuropathies From Nivolumab in a Patient With Metastatic Hepatocellular Carcinoma.

Siegel CH, Finn RS, Ho MG.

Mayo Clin Proc. 2018 Apr;93(4):540-541. doi: 10.1016/j.mayocp.2018.01.001. No abstract available.

PMID:
29622100
8.

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL.

Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.

PMID:
29433850
9.

Negative phase 3 study of 90Y microspheres versus sorafenib in HCC.

Llovet JM, Finn RS.

Lancet Oncol. 2018 Feb;19(2):e69. doi: 10.1016/S1470-2045(18)30025-1. No abstract available.

PMID:
29413470
10.

Corrigendum: Minimum information about a single amplified genome (MISAG) and a metagenome-assembled genome (MIMAG) of bacteria and archaea.

Bowers RM, Kyrpides NC, Stepanauskas R, Harmon-Smith M, Doud D, Reddy TBK, Schulz F, Jarett J, Rivers AR, Eloe-Fadrosh EA, Tringe SG, Ivanova NN, Copeland A, Clum A, Becraft ED, Malmstrom RR, Birren B, Podar M, Bork P, Weinstock GM, Garrity GM, Dodsworth JA, Yooseph S, Sutton G, Glöckner FO, Gilbert JA, Nelson WC, Hallam SJ, Jungbluth SP, Ettema TJG, Tighe S, Konstantinidis KT, Liu WT, Baker BJ, Rattei T, Eisen JA, Hedlund B, McMahon KD, Fierer N, Knight R, Finn R, Cochrane G, Karsch-Mizrachi I, Tyson GW, Rinke C; Genome Standards Consortium, Lapidus A, Meyer F, Yilmaz P, Parks DH, Eren AM, Schriml L, Banfield JF, Hugenholtz P, Woyke T.

Nat Biotechnol. 2018 Feb 6;36(2):196. doi: 10.1038/nbt0218-196a. No abstract available.

11.

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial.

Rugo HS, Diéras V, Gelmon KA, Finn RS, Slamon DJ, Martin M, Neven P, Shparyk Y, Mori A, Lu DR, Bhattacharyya H, Bartlett CH, Iyer S, Johnston S, Ettl J, Harbeck N.

Ann Oncol. 2018 Apr 1;29(4):888-894. doi: 10.1093/annonc/mdy012.

12.

Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer.

Durairaj C, Ruiz-Garcia A, Gauthier ER, Huang X, Lu DR, Hoffman JT, Finn RS, Joy AA, Ettl J, Rugo HS, Zheng J, Wilner KD, Wang DD.

Anticancer Drugs. 2018 Mar;29(3):271-280. doi: 10.1097/CAD.0000000000000589.

13.

Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases.

Turner NC, Finn RS, Martin M, Im SA, DeMichele A, Ettl J, Diéras V, Moulder S, Lipatov O, Colleoni M, Cristofanilli M, Lu DR, Mori A, Giorgetti C, Iyer S, Bartlett CH, Gelmon KA.

Ann Oncol. 2018 Mar 1;29(3):669-680. doi: 10.1093/annonc/mdx797.

14.

The HMMER Web Server for Protein Sequence Similarity Search.

Prakash A, Jeffryes M, Bateman A, Finn RD.

Curr Protoc Bioinformatics. 2017 Dec 8;60:3.15.1-3.15.23. doi: 10.1002/cpbi.40.

PMID:
29220076
15.

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.

Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T.

J Clin Oncol. 2018 Jan 20;36(3):276-282. doi: 10.1200/JCO.2017.75.5009. Epub 2017 Nov 28.

PMID:
29182496
16.

The MEROPS database of proteolytic enzymes, their substrates and inhibitors in 2017 and a comparison with peptidases in the PANTHER database.

Rawlings ND, Barrett AJ, Thomas PD, Huang X, Bateman A, Finn RD.

Nucleic Acids Res. 2018 Jan 4;46(D1):D624-D632. doi: 10.1093/nar/gkx1134.

17.

Rfam 13.0: shifting to a genome-centric resource for non-coding RNA families.

Kalvari I, Argasinska J, Quinones-Olvera N, Nawrocki EP, Rivas E, Eddy SR, Bateman A, Finn RD, Petrov AI.

Nucleic Acids Res. 2018 Jan 4;46(D1):D335-D342. doi: 10.1093/nar/gkx1038.

18.

Ensembl Genomes 2018: an integrated omics infrastructure for non-vertebrate species.

Kersey PJ, Allen JE, Allot A, Barba M, Boddu S, Bolt BJ, Carvalho-Silva D, Christensen M, Davis P, Grabmueller C, Kumar N, Liu Z, Maurel T, Moore B, McDowall MD, Maheswari U, Naamati G, Newman V, Ong CK, Paulini M, Pedro H, Perry E, Russell M, Sparrow H, Tapanari E, Taylor K, Vullo A, Williams G, Zadissia A, Olson A, Stein J, Wei S, Tello-Ruiz M, Ware D, Luciani A, Potter S, Finn RD, Urban M, Hammond-Kosack KE, Bolser DM, De Silva N, Howe KL, Langridge N, Maslen G, Staines DM, Yates A.

Nucleic Acids Res. 2018 Jan 4;46(D1):D802-D808. doi: 10.1093/nar/gkx1011.

19.

EBI Metagenomics in 2017: enriching the analysis of microbial communities, from sequence reads to assemblies.

Mitchell AL, Scheremetjew M, Denise H, Potter S, Tarkowska A, Qureshi M, Salazar GA, Pesseat S, Boland MA, Hunter FMI, Ten Hoopen P, Alako B, Amid C, Wilkinson DJ, Curtis TP, Cochrane G, Finn RD.

Nucleic Acids Res. 2018 Jan 4;46(D1):D726-D735. doi: 10.1093/nar/gkx967.

20.

Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions.

Tak WY, Lin SM, Wang Y, Zheng J, Vecchione A, Park SY, Chen MH, Wong S, Xu R, Peng CY, Chiou YY, Huang GT, Cai J, Abdullah BJJ, Lee JS, Lee JY, Choi JY, Gopez-Cervantes J, Sherman M, Finn RS, Omata M, O'Neal M, Makris L, Borys N, Poon R, Lencioni R.

Clin Cancer Res. 2018 Jan 1;24(1):73-83. doi: 10.1158/1078-0432.CCR-16-2433. Epub 2017 Oct 10.

PMID:
29018051
21.

Process development of a FGF21 protein-antibody conjugate.

Dirksen A, Davis KA, Collins JT, Bhattacharya K, Finneman JI, Pepin EL, Ryczek JS, Brown PW, Wellborn WB, Mangalathillam R, Evans BP, Pozzo MJ, Finn RF.

Biopolymers. 2017 Sep 26. doi: 10.1002/bip.23042. [Epub ahead of print]

PMID:
28948603
22.

Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: A systematic review and meta-analysis.

Finn RS, Zhu AX, Farah W, Almasri J, Zaiem F, Prokop LJ, Murad MH, Mohammed K.

Hepatology. 2018 Jan;67(1):422-435. doi: 10.1002/hep.29486. Review.

PMID:
28881497
23.

Review of Regorafenib for the Treatment of Hepatocellular Carcinoma.

Finn RS.

Gastroenterol Hepatol (N Y). 2017 Aug;13(8):492-495. No abstract available.

24.

Minimum information about a single amplified genome (MISAG) and a metagenome-assembled genome (MIMAG) of bacteria and archaea.

Bowers RM, Kyrpides NC, Stepanauskas R, Harmon-Smith M, Doud D, Reddy TBK, Schulz F, Jarett J, Rivers AR, Eloe-Fadrosh EA, Tringe SG, Ivanova NN, Copeland A, Clum A, Becraft ED, Malmstrom RR, Birren B, Podar M, Bork P, Weinstock GM, Garrity GM, Dodsworth JA, Yooseph S, Sutton G, Glöckner FO, Gilbert JA, Nelson WC, Hallam SJ, Jungbluth SP, Ettema TJG, Tighe S, Konstantinidis KT, Liu WT, Baker BJ, Rattei T, Eisen JA, Hedlund B, McMahon KD, Fierer N, Knight R, Finn R, Cochrane G, Karsch-Mizrachi I, Tyson GW, Rinke C; Genome Standards Consortium, Lapidus A, Meyer F, Yilmaz P, Parks DH, Eren AM, Schriml L, Banfield JF, Hugenholtz P, Woyke T.

Nat Biotechnol. 2017 Aug 8;35(8):725-731. doi: 10.1038/nbt.3893.

PMID:
28787424
25.

Stereotactic body radiotherapy (SBRT) for locally advanced extrahepatic and intrahepatic cholangiocarcinoma.

Sandler KA, Veruttipong D, Agopian VG, Finn RS, Hong JC, Kaldas FM, Sadeghi S, Busuttil RW, Lee P.

Adv Radiat Oncol. 2016 Oct 29;1(4):237-243. doi: 10.1016/j.adro.2016.10.008. eCollection 2016 Oct-Dec.

26.

Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients.

Gomes AS, Monteleone PA, Sayre JW, Finn RS, Sadeghi S, Tong MJ, Britten CD, Busuttil RW.

AJR Am J Roentgenol. 2017 Oct;209(4):722-732. doi: 10.2214/AJR.17.18219. Epub 2017 Jul 13.

PMID:
28705059
27.

Determination of hepatocellular carcinoma grade by needle biopsy is unreliable for liver transplant candidate selection.

Court CM, Harlander-Locke MP, Markovic D, French SW, Naini BV, Lu DS, Raman SS, Kaldas FM, Zarrinpar A, Farmer DG, Finn RS, Sadeghi S, Tomlinson JS, Busuttil RW, Agopian VG.

Liver Transpl. 2017 Sep;23(9):1123-1132. doi: 10.1002/lt.24811.

PMID:
28688158
28.

The metagenomic data life-cycle: standards and best practices.

Ten Hoopen P, Finn RD, Bongo LA, Corre E, Fosso B, Meyer F, Mitchell A, Pelletier E, Pesole G, Santamaria M, Willassen NP, Cochrane G.

Gigascience. 2017 Aug 1;6(8):1-11. doi: 10.1093/gigascience/gix047.

29.

ELIXIR pilot action: Marine metagenomics - towards a domain specific set of sustainable services.

Robertsen EM, Denise H, Mitchell A, Finn RD, Bongo LA, Willassen NP.

F1000Res. 2017 Jan 23;6. pii: ELIXIR-70. doi: 10.12688/f1000research.10443.1. eCollection 2017.

30.

Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach.

Sun W, O'Dwyer PJ, Finn RS, Ruiz-Garcia A, Shapiro GI, Schwartz GK, DeMichele A, Wang D.

J Clin Pharmacol. 2017 Sep;57(9):1159-1173. doi: 10.1002/jcph.902. Epub 2017 Apr 18.

PMID:
28419480
31.

Persisting risk of hepatocellular carcinoma after hepatitis C virus cure monitored by a liver transcriptome signature.

Ono A, Goossens N, Finn RS, Schmidt WN, Thung SN, Im GY, Hoshida Y; Precision Liver Cancer Prevention Consortium.

Hepatology. 2017 Oct;66(4):1344-1346. doi: 10.1002/hep.29203. Epub 2017 Aug 26. No abstract available.

PMID:
28390144
32.

Bolus Administration of Fentanyl and Midazolam for Colonoscopy Increases Endoscopy Unit Efficiency and Safety Compared With Titrated Sedation.

Finn RT 3rd, Boyd A, Lin L, Gellad ZF.

Clin Gastroenterol Hepatol. 2017 Sep;15(9):1419-1426.e2. doi: 10.1016/j.cgh.2017.03.030. Epub 2017 Mar 29.

PMID:
28365484
33.

The Physiological Role and Regulation of Aquaporins in Teleost Germ Cells.

Cerdà J, Chauvigné F, Finn RN.

Adv Exp Med Biol. 2017;969:149-171. doi: 10.1007/978-94-024-1057-0_10. Review.

PMID:
28258572
34.

Cohesin biology meets the loop extrusion model.

Barrington C, Finn R, Hadjur S.

Chromosome Res. 2017 Mar;25(1):51-60. doi: 10.1007/s10577-017-9550-3. Epub 2017 Feb 16. Review.

35.

Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: A 10-year intention-to-treat analysis.

Lee MW, Raman SS, Asvadi NH, Siripongsakun S, Hicks RM, Chen J, Worakitsitisatorn A, McWilliams J, Tong MJ, Finn RS, Agopian VG, Busuttil RW, Lu DSK.

Hepatology. 2017 Jun;65(6):1979-1990. doi: 10.1002/hep.29098. Epub 2017 Apr 28.

PMID:
28170115
36.

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.

Bendell JC, Javle M, Bekaii-Saab TS, Finn RS, Wainberg ZA, Laheru DA, Weekes CD, Tan BR, Khan GN, Zalupski MM, Infante JR, Jones S, Papadopoulos KP, Tolcher AW, Chavira RE, Christy-Bittel JL, Barrett E, Patnaik A.

Br J Cancer. 2017 Feb 28;116(5):575-583. doi: 10.1038/bjc.2017.10. Epub 2017 Feb 2.

37.

AASLD guidelines for the treatment of hepatocellular carcinoma.

Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA.

Hepatology. 2018 Jan;67(1):358-380. doi: 10.1002/hep.29086. No abstract available.

PMID:
28130846
38.

Lung disease severity in idiopathic pulmonary fibrosis is more strongly associated with impedance measures of bolus reflux than pH parameters of acid reflux alone.

Gavini S, Borges LF, Finn RT, Lo WK, Goldberg HJ, Burakoff R, Feldman N, Chan WW.

Neurogastroenterol Motil. 2017 May;29(5). doi: 10.1111/nmo.13001. Epub 2016 Dec 16.

PMID:
27987250
39.

Palbociclib and Letrozole in Advanced Breast Cancer.

Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Diéras V, Slamon DJ.

N Engl J Med. 2016 Nov 17;375(20):1925-1936.

40.

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G; RESORCE Investigators.

Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6. Erratum in: Lancet. 2017 Jan 7;389(10064):36.

PMID:
27932229
41.

The role of liver biopsy in hepatocellular carcinoma.

Finn RS.

Clin Adv Hematol Oncol. 2016 Oct;14(10):759-761. No abstract available.

PMID:
27930626
42.

Novel second-line treatments for hepatocellular carcinoma: Discussion.

Frenette CT, Lencioni R, Finn RS.

Clin Adv Hematol Oncol. 2016 Dec;14 Suppl 12(12):12-13. No abstract available.

PMID:
27930619
43.

Developing a treatment plan for hepatocellular carcinoma: the continuum of care.

Finn RS.

Clin Adv Hematol Oncol. 2016 Dec;14 Suppl 12(12):9-11. No abstract available.

PMID:
27930618
44.

The Role of Liver Biopsy in Hepatocellular Carcinoma.

Finn RS.

Gastroenterol Hepatol (N Y). 2016 Oct;12(10):628-630. No abstract available.

45.

InterPro in 2017-beyond protein family and domain annotations.

Finn RD, Attwood TK, Babbitt PC, Bateman A, Bork P, Bridge AJ, Chang HY, Dosztányi Z, El-Gebali S, Fraser M, Gough J, Haft D, Holliday GL, Huang H, Huang X, Letunic I, Lopez R, Lu S, Marchler-Bauer A, Mi H, Mistry J, Natale DA, Necci M, Nuka G, Orengo CA, Park Y, Pesseat S, Piovesan D, Potter SC, Rawlings ND, Redaschi N, Richardson L, Rivoire C, Sangrador-Vegas A, Sigrist C, Sillitoe I, Smithers B, Squizzato S, Sutton G, Thanki N, Thomas PD, Tosatto SC, Wu CH, Xenarios I, Yeh LS, Young SY, Mitchell AL.

Nucleic Acids Res. 2017 Jan 4;45(D1):D190-D199. doi: 10.1093/nar/gkw1107. Epub 2016 Nov 29.

46.

Problems and complications of full-face carbon dioxide laser resurfacing for pathological lesions of the skin.

Read-Fuller AM, Yates DM, Vu DD, Hoopman JE, Finn RA.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Jan;123(1):e10-e15. doi: 10.1016/j.oooo.2016.08.012. Epub 2016 Aug 23.

PMID:
27727108
47.

Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells.

Shi Y, Daniels-Wells TR, Frost P, Lee J, Finn RS, Bardeleben C, Penichet ML, Jung ME, Gera J, Lichtenstein A.

Cancer Res. 2016 Oct 1;76(19):5822-5831. Epub 2016 Aug 16.

48.

Maximum Quantity of Bone Available for Harvest From the Anterior Iliac Crest, Posterior Iliac Crest, and Proximal Tibia Using a Standardized Surgical Approach: A Cadaveric Study.

Burk T, Del Valle J, Finn RA, Phillips C.

J Oral Maxillofac Surg. 2016 Dec;74(12):2532-2548. doi: 10.1016/j.joms.2016.06.191. Epub 2016 Jul 21.

PMID:
27524516
49.

Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection.

Zhang B, Finn RS.

Liver Cancer. 2016 Jul;5(3):221-32. doi: 10.1159/000367763. Epub 2016 May 10. Review.

50.

Molecular and functional characterization of Bemisia tabaci aquaporins reveals the water channel diversity of hemipteran insects.

Van Ekert E, Chauvigné F, Finn RN, Mathew LG, Hull JJ, Cerdà J, Fabrick JA.

Insect Biochem Mol Biol. 2016 Oct;77:39-51. doi: 10.1016/j.ibmb.2016.07.010. Epub 2016 Aug 2.

PMID:
27491441

Supplemental Content

Support Center